Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 8:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 514 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diabetes Mellitus, Type 1, Type 2 Clear all
Terminated Phase 4 Interventional

Patient Preference of h-Patch vs. Pen or Needle/Syringe as Insulin Administration Device

NCT00453934
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
h-Patch
Device
Lead sponsor
Valeritas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Jul 24, 2026, 8:04 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus

NCT07160257
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Maridebart cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 24, 2026, 8:04 AM EDT
Completed Phase 3 Interventional Results available

Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes

NCT01045707
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/insulin aspart, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
41
States / cities
Birmingham, Alabama • Vestavia Hills, Alabama • Concord, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Jul 24, 2026, 8:04 AM EDT
Completed Phase 1 Interventional Results available

Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes

NCT01272804
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, NIDDM
Interventions
PF-04937319, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
4
States / cities
Miami, Florida • South Miami, Florida • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Jul 24, 2026, 8:04 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes

NCT00612040
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
Walnut Creek, California • Honolulu, Hawaii • Idaho Falls, Idaho + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jul 24, 2026, 8:04 AM EDT
Completed Not applicable Interventional Results available

Two Way Crossover Closed Loop Study R-AP vs MPC

NCT05083559
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
MPC AP algorithm, Robust R-AP algorithm
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Jul 24, 2026, 8:04 AM EDT
Active, not recruiting Phase 2 Interventional

Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

NCT05743244
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 35 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
23
States / cities
Orange, California • Palo Alto, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 24, 2026, 8:04 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Community Models for Hypertension and Diabetes Care for Refugees

NCT04229667
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Comorbidities and Coexisting Conditions
Interventions
Improved Community Health Volunteer (CHV) program
Other
Lead sponsor
International Rescue Committee
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Jul 24, 2026, 8:04 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

NCT06562907
View directory record Official record
Conditions
Weight Management
Interventions
GS-4571, Placebo, Omeprazole
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Miami, Florida • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 24, 2026, 8:04 AM EDT
Completed Phase 2 Interventional

Evaluation of the Bioavailability of Pramlintide

NCT00042471
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
4
States / cities
Orlando, Florida • New Orleans, Louisiana • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2015 · Synced Jul 24, 2026, 8:04 AM EDT
Not listed No phase listed Observational

Bigfoot Unity Real World Study

NCT05088265
View directory record Official record
Conditions
Type 1 or Type 2 Diabetes
Interventions
Bigfoot Unity Diabetes Management System
Device
Lead sponsor
Bigfoot Biomedical Inc.
Industry
Eligibility
12 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Milpitas, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Jul 24, 2026, 8:04 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

NCT07167693
View directory record Official record
Conditions
Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions
Arginine hydrochloride, Sodium Chloride 0.9%
Drug
Lead sponsor
David K Carroll
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jul 24, 2026, 8:04 AM EDT
Terminated Phase 1 Interventional

Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus

NCT00637338
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-04603629, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
4
States / cities
Phoenix, Arizona • Miami, Florida • Wichita, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2009 · Synced Jul 24, 2026, 8:04 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Impact of Metabolic Health on Sperm Epigenetic Marks in Humans

NCT03860558
View directory record Official record
Conditions
Overweight, Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus
Interventions
Lifestyle Intervention, No Intervention
Other
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jul 24, 2026, 8:04 AM EDT
Completed No phase listed Observational

Accuracy Comparison of Two CGMs in Hospitalized Patients

NCT05081817
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Jul 24, 2026, 8:04 AM EDT
Completed Phase 2 Interventional Results available

BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes

NCT01498185
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Dapagliflozin, Placebo matching Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
12
States / cities
Chula Vista, California • San Diego, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Jul 24, 2026, 8:04 AM EDT
Withdrawn Phase 4 Interventional

Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery

NCT01971047
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Regular Insulin, Humalog
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Jul 24, 2026, 8:04 AM EDT
Completed Not applicable Interventional

A Primary Care, EHR- Based Strategy to Promote Safe and Appropriate Drug Use

NCT01669473
View directory record Official record
Conditions
Diabetes Mellitus Type I, Diabetes Mellitus Type II
Interventions
EHR Based Strategy to promote Safe and Appropriate Drug Use
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 90 Years
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Jul 24, 2026, 8:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants

NCT06293742
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
ECC5004, Midazolam, Rosuvastatin, Digoxin, Atorvastatin
Drug
Lead sponsor
Eccogene
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2024 · Synced Jul 24, 2026, 8:04 AM EDT
Terminated Phase 3 Interventional

Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma

NCT00523042
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Asthma
Interventions
insulin aspart, inhaled human insulin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Fresno, California • New Orleans, Louisiana • Kansas City, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Jul 24, 2026, 8:04 AM EDT
Completed Phase 2 Interventional

Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

NCT01452451
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
HM11260C, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Ohio City, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Jul 24, 2026, 8:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function

NCT01478399
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PB1023 Injection
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Saint Paul, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 14, 2013 · Synced Jul 24, 2026, 8:04 AM EDT
Completed Not applicable Interventional

Breakfast Nutrition and Inpatient Glycemia

NCT01805414
View directory record Official record
Conditions
Diabetes, Type 1, Diabetes, Type 2, Cardiovascular Disease, Hyperglycemia
Interventions
Modified Carbohydrate Breakfast, Control Breakfast
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Jul 24, 2026, 8:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Financial Incentives Telephone Education and Skills Trial in African Americans With Diabetes (FITEST)

NCT02722499
View directory record Official record
Conditions
Diabetes Mellitus, Type 2 Diabetes Mellitus, Adult-Onset Diabetes Mellitus, Non-Insulin-Dependent Diabetes Mellitus, Noninsulin Dependent Diabetes Mellitus, Type II
Interventions
High Frequency Financial Incentive, Moderate Frequency Financial Incentive, Low Frequency Financial Incentive
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
21 Years to 100 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Jul 24, 2026, 8:04 AM EDT